$NPLS
NP Life Sciences Health Industry Group Inc.

2023 Q2 Form 10-K Financial Statement

#000149315223012632 Filed on April 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $107.1K $46.02K $102.0K
YoY Change 614.85% 31.52% 240.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $35.71K $29.42K $120.9K
YoY Change 156.72% 981.62% 20.86%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $35.71K $29.42K $120.9K
YoY Change 156.72% 981.62% 20.86%
Operating Profit $71.39K -$18.86K
YoY Change 6528.78% -71.29%
Interest Expense -$200.00 $0.00 $0.00
YoY Change
% of Operating Profit -0.28%
Other Income/Expense, Net -$197.00 -$1.00
YoY Change -19800.0% -125.0%
Pretax Income $71.20K $16.60K -$18.86K
YoY Change 6510.96% -48.56% -73.06%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $71.20K $16.60K -$18.86K
YoY Change 6504.36% -48.56% -73.06%
Net Earnings / Revenue 66.48% 36.07% -18.49%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 42.96M shares 42.96M shares 42.96M shares
Diluted Shares Outstanding 42.96M shares 42.96M shares

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.1K $121.9K
YoY Change 21470.69% 335.37%
Cash & Equivalents $125.1K $121.9K
Short-Term Investments
Other Short-Term Assets $19.00K $5.930K
YoY Change 15.43% -43.14%
Inventory
Prepaid Expenses $19.00K $5.925K
Receivables
Other Receivables
Total Short-Term Assets $144.1K $127.8K
YoY Change 745.72% 232.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$4.00 $4.00
YoY Change -20.0% 300.0%
TOTAL ASSETS
Total Short-Term Assets $144.1K $127.8K
Total Long-Term Assets -$4.00 $4.00
Total Assets $144.1K $127.8K
YoY Change 745.94% 232.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.025K $6.130K
YoY Change 55.4%
Accrued Expenses $3.194K $2.739K
YoY Change -36.12% 1046.03%
Deferred Revenue $7.500K $99.60K
YoY Change
Short-Term Debt $22.36K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $77.00K $108.5K
YoY Change 767.12% 45095.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $77.00K $108.5K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $77.00K $108.5K
YoY Change 767.35% 45284.1%
SHAREHOLDERS EQUITY
Retained Earnings -$297.5K -$345.3K
YoY Change -16.54% 5.78%
Common Stock $4.296K $4.296K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.11K $19.32K
YoY Change
Total Liabilities & Shareholders Equity $144.1K $127.8K
YoY Change 745.94% 232.68%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $71.20K $16.60K -$18.86K
YoY Change 6504.36% -48.56% -73.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$37.33K $93.87K $93.87K
YoY Change 65.54% 3060.61% -204.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.36K
YoY Change
NET CHANGE
Cash From Operating Activities -37.33K 93.87K $93.87K
Cash From Investing Activities
Cash From Financing Activities 22.36K
Net Change In Cash -14.97K 93.87K $93.87K
YoY Change -33.61% 3060.61% -204.3%
FREE CASH FLOW
Cash From Operating Activities -$37.33K $93.87K $93.87K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001781726
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Auditor Firm
AuditorFirmId
1171
CY2022 dei Auditor Location
AuditorLocation
San Mateo, CA
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121859 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27986 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-56140
CY2022 dei Entity Registrant Name
EntityRegistrantName
NP Life Sciences Health Industry Group Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2912878
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4125 Blackhawk Plaza Circle
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 166
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Danville
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94506
CY2022 dei City Area Code
CityAreaCode
(925)
CY2022 dei Local Phone Number
LocalPhoneNumber
362-3169
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022 dei Trading Symbol
TradingSymbol
NPLS
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42959574 shares
CY2022 dei Auditor Name
AuditorName
WWC, P.C.
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5925 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10425 usd
CY2022Q4 us-gaap Assets
Assets
127784 usd
CY2021Q4 us-gaap Assets
Assets
38411 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
99599 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6130 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2739 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
239 usd
CY2022Q4 us-gaap Liabilities
Liabilities
108468 usd
CY2021Q4 us-gaap Liabilities
Liabilities
239 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42959574 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42959574 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42959574 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42959574 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4296 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4296 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
360330 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
360330 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345310 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326454 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19316 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127784 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38411 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102002 usd
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34992 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
120857 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
100673 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-18855 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-65681 usd
CY2022 NPLS Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-18855 usd
CY2021 NPLS Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-65681 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18856 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65677 usd
CY2022 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-18856 usd
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-65677 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
103849 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65677 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18856 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19316 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19316 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18856 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65677 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4500 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10425 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6130 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
99599 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2500 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14523 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
93873 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90625 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
93873 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90625 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27986 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118611 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121859 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27986 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_802_eus-gaap--NatureOfOperations_zdYovQnwMdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zvnzHV7MRxk9">NATURE OF OPERATIONS</span></b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NP Life Sciences Health Industry Group Inc. (the “Company”) is a for profit corporation established under the corporation laws in the State of Nevada, United States of America on December 20, 2018. The Company was originally incorporated as “Guojiang Cultural Industry US, Inc.” and amended the name to “GJ Culture Group US, Inc.” on February 20, 2019. On September 8, 2022, the Company filed a Certificate of Amendment to its Articles of Incorporation with the State of Nevada to reflect its corporate name change from “GJ Culture Group US, Inc.” to “NP Life Sciences Health Industry Group Inc.”. The name change was effective as of the filing of the Certificate of Amendment with the State of Nevada. The Company is awaiting the approval of FINRA for the market effectiveness of the name change. Unless the context otherwise requires, all references to “NP Life Sciences Health Industry Group Inc.,” “GJ Culture Group US, Inc.,” “we,” “us,” “our” or the “Company” are to NP Life Sciences Health Industry Group Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is dedicated to providing educational services based on classical Chinese studies and culture. The Company’s goal is to serve as cultural and educational meeting point between China and the U.S. The Company intends to pursue its business objective by providing education and training courses based on classical Chinese studies, organizing China-U.S. international study tour activities for participants of all ages, as well as organizing and promoting China-U.S. cultural events, art fairs, exhibitions, and other activities promoting Chinese culture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 8, 2022, the Company established a wholly-owned subsidiary GW Health Consulting Management Inc. (“herein after referred to as “GW”), a California Corporation. GW’s current business is limited to providing online career planning experience sharing and guidance related consulting services. </span></p>
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345310 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zQv0be65LRne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zEEpBZM40sQk">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the limited level of operations, the Company has not needed to make material assumptions or estimates other than the assumption that the Company is a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
99599 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
99599 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
99599 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18856 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65677 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
345310 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
326454 usd

Files In Submission

Name View Source Status
0001493152-23-012632-index-headers.html Edgar Link pending
0001493152-23-012632-index.html Edgar Link pending
0001493152-23-012632.txt Edgar Link pending
0001493152-23-012632-xbrl.zip Edgar Link pending
auditreport_001.jpg Edgar Link pending
auditreport_002.jpg Edgar Link pending
auditreport_003.jpg Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_002.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
form10-k_004.jpg Edgar Link pending
form10-k_005.jpg Edgar Link pending
form10-k_006.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
npls-20221231.xsd Edgar Link pending
form10-k_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
npls-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
npls-20221231_cal.xml Edgar Link unprocessable
npls-20221231_def.xml Edgar Link unprocessable
npls-20221231_pre.xml Edgar Link unprocessable